These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18946746)

  • 21. Recent topics in endocrine therapy for hormone-dependent breast cancer: basic research and clinical applications.
    Kimijima I
    Breast Cancer; 2008; 15(4):253-5. PubMed ID: 18953680
    [No Abstract]   [Full Text] [Related]  

  • 22. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
    Come SE; Buzdar AU; Ingle JN; Arteaga CL; Brown M; Dowsett M; Hilsenbeck SG; Kumar R; Johnston SR; Lee AV; Paik S; Pritchard KI; Winer EP; Hart C
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):997s-1000s. PubMed ID: 16467115
    [No Abstract]   [Full Text] [Related]  

  • 23. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers.
    Purohit A; Foster PA
    J Endocrinol; 2012 Feb; 212(2):99-110. PubMed ID: 21859802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal treatment of endometrial carcinoma.
    Baekelandt M
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):106-12. PubMed ID: 12113059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone treatments in the common 'hormone-dependent' carcinomas.
    Wood BC
    Palliat Med; 1993; 7(4):257-72. PubMed ID: 7505186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing concepts of hormone receptor-positive advanced breast cancer therapy.
    Chlebowski RT
    Clin Breast Cancer; 2013 Jun; 13(3):159-66. PubMed ID: 23228361
    [No Abstract]   [Full Text] [Related]  

  • 27. [Endocrine therapy for postmenopausal breast cancer (role of cycline D1)].
    Manikhas AG; Skvortsov VA; Manikhas GM; Raskin GA; Oganesian AS; Shemerovskiĭ AK
    Vopr Onkol; 2011; 57(5):641-4. PubMed ID: 22238936
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of endocrine therapy.
    Pritchard KI; Sutherland DJ
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):765-805. PubMed ID: 2481670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Breast cancer subtypes and their endocrine-metabolic basis; practical aspects].
    Bershteĭn LM; Semiglazov VF
    Vopr Onkol; 2011; 57(5):559-66. PubMed ID: 22238924
    [No Abstract]   [Full Text] [Related]  

  • 30. Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit?
    Pignata S; Daniele B; Gallo C; De Vivo R; Monfardini S; Perrone F
    Eur J Cancer; 1998 Jan; 34(1):25-32. PubMed ID: 9624234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting rapid action of sex steroid receptors in breast and prostate cancers.
    Giovannelli P; Di Donato M; Giraldi T; Migliaccio A; Castoria G; Auricchio F
    Front Biosci (Landmark Ed); 2011 Jun; 16(6):2224-32. PubMed ID: 21622172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 33. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 34. Steroid hormones and cancer: (III) observations from human subjects.
    Miller WR; Langdon SP
    Eur J Surg Oncol; 1997 Apr; 23(2):163-77; quiz 177-8, 183. PubMed ID: 9158194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Sgroi DC; Haber DA; Ryan PD; Ma XJ; Erlander MG
    Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
    [No Abstract]   [Full Text] [Related]  

  • 36. [Basic and clinical characteristics of flutamide].
    Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
    [No Abstract]   [Full Text] [Related]  

  • 37. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure to report financial disclosure information.
    Lu-Yao G; Albertsen P; Shih W; Yao SL
    JAMA; 2009 Jan; 301(1):35-6. PubMed ID: 19126808
    [No Abstract]   [Full Text] [Related]  

  • 39. Aromatase in the context of breast and endometrial cancer. A review.
    Jongen VH; Hollema H; Van Der Zee AG; Heineman MJ
    Minerva Endocrinol; 2006 Mar; 31(1):47-60. PubMed ID: 16498363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary androgen deprivation therapy in men with prostate cancer.
    Laufman L
    JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.